PSMA PET Imaging of Recurrent Prostate Cancer


Condition: Prostate Adenocarcinoma, Prostate Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03204123

Sponsor: Memorial Sloan Kettering Cancer Center

Phase: Phase 2

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • Biopsy proven adenocarcinoma of the prostate
  • Initially treated with definitive local therapy (surgery and radiation therapy are the most common treatments, but other treatments are also eligible)
  • For patients initially treated with surgery, radiation therapy, brachytherapy, or cryotherapy:
  • PSA ≥ 0.2 ng/mL in at least two consecutive tests within 6 months of date of consent for patients
  • Note: The most recent PSA value must be within 6 weeks of consent
  • For patients who have received additional treatment in the recurrent or metastatic setting: ° PSA ≥ 2 ng/ml above the most recent therapy nadir
  • Age ≥ 18 years
  • Patient must be able to tolerate PET/CT or PET/MR imaging

Exclusion Criteria:

  • Patient with claustrophobia that would preclude PET/CT or PET/MR imaging or other contraindications to CT imaging.

View trial on ClinicalTrials.gov


email news signup